ArriVent BioPharma, Inc. - Common Stock (AVBP)

28.54Last Price

-0.55 (-1.89%)Change

ArriVent BioPharma, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies to address unmet medical needs in various disease areas

The company leverages cutting-edge research and advanced clinical development strategies to create targeted treatments, particularly in oncology and other serious diseases. By prioritizing scientific rigor and collaborative partnerships, ArriVent aims to bring transformative solutions to patients and improve health outcomes globally.

ArriVent BioPharma Reports First Quarter 2024 Financial Results

NEWTOWN SQUARE, Pa., May 08, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“Company” or “ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the first quarter ended March 31, 2024, and highlighted recent Company progress.

By ArriVent BioPharma, Inc. · Via GlobeNewswire · May 8, 2024

ArriVent Appoints Kristine Peterson to its Board of Directors

NEWTON SQUARE, Pa., April 22, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Kristine Peterson to its Board of Directors. Ms. Peterson brings over 30 years of biopharmaceutical leadership experience, and currently serves on the Boards of public companies Immunocore, Inc. and Enanta Pharmaceuticals.

By ArriVent BioPharma, Inc. · Via GlobeNewswire · April 22, 2024